miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies

作     者：Iris Garrido-Cano Anna Adam-Artigues Ana Lameirinhas Juan F.Blandez Vicente Candela-Noguera Federico Rojo Sandra Zazo Juan Madoz-Gúrpide Ana Lluch Begoña Bermejo Felix Sancenón Juan Miguel Cejalvo Ramón Martínez-Mañez Pilar Eroles 

作者机构：Biomedical Research Institute INCLIVAValencia 46010Spain BioengineeringBiomaterials and Nanomedicine Networking Biomedical Research Centre(CIBER-BBN)Madrid 28029Spain Interuniversity Research Institute for Molecular Recognition and Technological Development(IDM)Polytechnic University of ValenciaUniversity of ValenciaValencia 46010Spain Joint Unit CIPF-UPV of Mechanisms of Diseases and NanomedicineValenciaPolytechnic University of ValenciaPrince Felipe Research CenterValencia 46012Spain Joint Research Unit in Nanomedicine and SensorsPolytechnic University of ValenciaMedical Research Institute Hospital La FeValencia 46026Spain Biomedical Research Networking Center in Oncology(CIBERONC)Madrid 28029Spain Department of PathologyFundación Jiménez Díaz University Hospital Health Research InstituteMadrid 28040Spain Department of Clinical OncologyUniversity Clinical Hospital of ValenciaValencia 46010Spain Department of MedicineUniversity of ValenciaValencia 46010Spain Department of PhysiologyUniversity of ValenciaValencia 46010Spain 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2022年第42卷第12期

页      面：1412-1416页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by Spanish Government and cofinanced by FEDER Funds(PI18/01219,PI21/01351,PI18/00382,and RTI2018-100910-B-C41) CIBERBBN(CB07/01/2012) CIBERONC(CB16/12/00481) the Generalitat Valenciana(project PROMETEO 2018/024) funded by Generalitat Valenciana(ACIF/2016/030) funded by Asociación Española Contra el Cancer. funded by Instituto de Salud Carlos Ⅲ and the European Social Fund for the financial support“Sara Borrell”(CD19/00038) funded by Ministerio de Ciencia e Innovación(FPU grant) funded by Sociedad Española de Oncología Médica(Río Hortega-SEOM). 

主　　题：doxorubicin ABCG2 chemotherapy 

摘      要：Dear Editor,Breast cancer(BC)is the most commonly diagnosed cancer and the fifth cause of cancer-related death worldwide[1].Despite the advances in BC targeted therapies,cytotoxic chemotherapy is still widely used[2].However,around 20%-30%of BC patients develop metastasis after treatment as a consequence of drug resistance[3].In this context,microRNAs have emerged as potential therapeutic targets to overcome therapy resistance[4].Therefore,we aimed to elucidate the molecular mechanisms underlying resistance to doxorubicin,one of the most effective chemotherapeutic agents used in BC.Methods are detailed in Supplementary Materials.